Shares of Alimera Sciences Inc. (NASDAQ:ALIM) fell 1.4% during trading on Friday . The company traded as low as $1.85 and last traded at $2.04, with a volume of 2,805,753 shares traded. The stock had previously closed at $2.07.

A number of research firms have recently commented on ALIM. Cowen and Company reissued a “hold” rating on shares of Alimera Sciences in a research note on Tuesday. Zacks Investment Research raised Alimera Sciences from a “sell” rating to a “hold” rating and set a $1.50 price objective on the stock in a research note on Wednesday, July 6th.

The stock’s market cap is $92.45 million. The company has a 50 day moving average price of $1.42 and a 200-day moving average price of $1.82.

Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.03. During the same quarter in the prior year, the company posted ($0.27) EPS. The firm earned $5.80 million during the quarter, compared to the consensus estimate of $5.83 million. The company’s revenue for the quarter was up 48.7% on a year-over-year basis. On average, analysts forecast that Alimera Sciences Inc. will post ($0.73) earnings per share for the current fiscal year.

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.